Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Cheuvreux – 11th German Corporate Conference (January 2012)
27 slides from Fresenius SE & Co. KGaA's conference presentation, Jan 17, 2012
Slide 1: Cheuvreux – 11th German Corporate Conference
Cheuvreux – 11th German Corporate Conference January 17, 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Slide 3: Achieving Profitable Growth in Attractive Health Care Segments
Achieving Profitable Growth in Attractive Health Care Segments Frankfurt listing (DAX30): FRE 100% Fresenius US ADR program (OTC): FSNUY Biotech Sales 2010: €16.0 bn EBIT 2010: €2,418 m Oncology and Immunology Therapies EBIT 2010: -€32 m 30% 100% 100% 77% Fresenius Fresenius Fresenius Fresenius Medi
Slide 4: Fresenius Group: Financial Results
Fresenius Group: Financial Results €m 15,972 Sales 5-year CAGR: 10% 14,164 +8% cc 12,336 2,418 EBIT 11,358 5-year CAGR: 14% 10,777 +13% cc 2,054 660 Net Income 1,727 5-year CAGR: 19% +23% cc 1,609 514 1,444 450 410 330 2006 2007 2008 2009 2010 Group financial results before APP-transaction-related s
Slide 5: Fresenius Group: Financial Results
Fresenius Group: Financial Results Sales EBIT Net income1 Q1-3/11 €12,089 m €1,862 m €565 m Growth at constant 5% 9% 17% currency rates Growth at actual 2% 5% 14% currency rates 1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting Cheuvreux – 11
Slide 6: Fresenius Group: Financial Results by Business Segment
Fresenius Group: Financial Results by Business Segment Q1-3/11 Fresenius Fresenius Fresenius Fresenius Medical Care Kabi Helios Vamed Sales US$9,473 m €2,950 m €1,950 m €480 m Growth 7% 8% 6% -7% EBIT US$1,488 m €613 m €195 m €22 m Growth 7% 10% 13% -8% Cheuvreux – 11th German Corporate Conference,
Slide 7: Fresenius Kabi: Update Q1-3/11
Fresenius Kabi: Update Q1-3/11 - 3% organic sales growth in Q3, leading to 9% growth in Q1-3; outstanding Q1-3 EBIT margin of 20.8% - 9% organic sales growth outside North America - 15% growth in Emerging Markets – China as largest contributor (+21%) - 19% growth in I.V. drugs – broad-based portfoli
Slide 8: Fresenius Kabi: Save the Date! Capital Market Day
Fresenius Kabi: Save the Date! Fresenius Kabi Capital Market Day Business – Strategy – Growth Prospects Scheduled June 12, 2012, Bad Homburg, Germany Cheuvreux – 11th German Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, January 17, 2012 Page 8
Slide 9: Fresenius Helios: Update Q1-3/11
Fresenius Helios: Update Q1-3/11 - Operating business in great shape: HELIOS hospital network pro forma, 4% organic sales growth; 70 bps EBIT margin including Damp Group and Duisburg Hospital increase to 10.0%; Q3 EBIT margin of 11.0% at all-time high - Hospital acquisitions provide significant grow
Slide 10: Fresenius Vamed: Update Q1-3/11
Fresenius Vamed: Update Q1-3/11 - Sales and earnings fully in line with expectations - Negative sales growth due to 2010 Ukraine project and Middle East/North Africa unrest - >10% sales growth adjusted for Ukraine/Middle East/North Africa - Excellent Q3 order intake of €171 million - €98 million hos
Slide 11: Fresenius Group: 2011 Outlook by Business Segment
Fresenius Group: 2011 Outlook by Business Segment Fresenius Sales growth ~US$13.0 bn Medical Care Net income US$1,070 – 1,090 m Fresenius Sales growth 8.0 – 8.5% organic Kabi EBIT margin 20% Fresenius Sales growth 3 – 5% organic Helios EBIT €260 – 270 m Fresenius Sales growth 0 – 5% - low end of ra
Slide 12: Fresenius Group: 2011 Outlook
Fresenius Group: 2011 Outlook Revenue growth ~6% at constant currency Net income growth1 ~18% at constant currency Capex ~5% of Group sales 1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting Cheuvreux – 11th German Corporate Conference, Fresen
Slide 13: Fresenius Group: Where are we Heading Mid term?
Fresenius Group: Where are we Heading Mid term? Average organic revenue growth of 6 – 9% Additional growth through small / mid-sized acquisitions Focus on quality and cost leadership Mid-term stretch financial goal: Group net income >€1 bn by 2014 Cheuvreux – 11th German Corporate Conference, Fresen
Slide 14: Attachments
Attachments Untertitel der Kapiteltrennseite Maximal zweizeilig, 18 pt Cheuvreux – 11th German Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, January 17, 2012 Page 14
Slide 15: Fresenius Group: Profit and Loss Statement
Fresenius Group: Profit and Loss Statement Growth at constant rates €m Q3/11 Q1-3/11 Q3/11 Q1-3/11 Sales 4,085 12,089 3% 5% EBIT 655 1,862 5% 9% Net interest -125 -401 8% 2% Income taxes -163 -451 -2% -8% Net income1 202 565 9% 17% 1 Net income attributable to Fresenius SE & Co. KGaA and before spec
Slide 16: Fresenius Group: Cash Flow
Fresenius Group: Cash Flow €m Q3/11 LTM Q3/10 LTM Growth Margin Margin YoY Operating Cash Flow 506 10.6% 541 11.4% -6% Capex (net) -183 -4.4% -171 -4.5% -7% Free Cash Flow 323 6.2% 370 6.9% -13% (before acquisitions and dividends) Acquisitions (net) -35 -68 49% Dividends -35 -12 -192% Free Cash Flow
Slide 17: Cash Flow Development LTM
Cash Flow Development LTM €m Operating CF Capex (net) Free Cash Flow1 LTM Q1-3/11 LTM Margin LTM Q1-3/11 LTM Margin LTM Q1-3/11 LTM Margin 539 13.8% (176) (4.5%) 363 9.3% 297 11.3% (128) (4.9%) 169 6.4% 3 -11 -1.6% (6) (0.9%) -17 -2.5% Corporate/ Other -30 n/a (12) n/a -42 n/a 2 excl. FMC 795 11.8%
Slide 18: Fresenius Group: Debt and Interest Ratios
Fresenius Group: Debt and Interest Ratios Net debt/EBITDA Sept 30, Dec 31, 2011 2010 3.64 3.65 Target 2011: Debt (€m) 9,181 8,784 3.51 3.50 3.46 2.5 – 3.0 thereof 54% US$ denominated 3.28 3.40 3.16 Net debt (€m) 8,527 8,015 3.07 3.03 3.13 3.01 2.95 Net debt/EBITDA 2.70 2.62 2.92 2.71 2.75 2.70 2.63
Slide 19: Fresenius Kabi: Strong Organic Sales Growth
Fresenius Kabi: Strong Organic Sales Growth €m Q1-3/11 Q1-3/10 Organic Growth Infusion Therapy 665 628 3% I.V. Drugs 1,076 982 14% Clinical Nutrition 855 789 9% Medical Devices/ Transfusion Technology 354 324 9% Total sales 2,950 2,723 9% Cheuvreux – 11th German Corporate Conference, Fresenius SE &
Slide 20: Fresenius Kabi: Strong Organic Sales Growth
Fresenius Kabi: Strong Organic Sales Growth €m Q1-3/11 Q1-3/10 Organic Growth Europe 1,360 1,264 6% North America 755 730 10% Asia-Pacific 511 436 18% Latin America/Africa 324 293 11% Total sales 2,950 2,723 9% Cheuvreux – 11th German Corporate Conference, Fresenius SE & Co. KGaA, Investor Relations
Slide 21: Fresenius Kabi: Excellent EBIT Growth
Fresenius Kabi: Excellent EBIT Growth €m Q1-3/11 Q1-3/10 Growth Europe 284 269 6% Margin 20.9% 21.3% North America 288 242 19% Margin 38.1% 33.2% Asia-Pacific/Latin America/Africa 169 134 26% Margin 20.2% 18.4% Corporate and Corporate R&D -128 -88 -45% Total EBIT 613 557 10% Margin 20.8% 20.5% Cheuv
Slide 22: Fresenius Helios: Excellent Sales and EBIT Growth
Fresenius Helios: Excellent Sales and EBIT Growth €m Q1-3/11 Q1-3/10 Growth Total sales 1,950 1,840 6% EBIT Established clinic portfolio 199 172 16% Margin 10.4% 9.3% Acquisitions -4 (consolidation < 1 yr) Total EBIT 195 172 13% Margin 10.0% 9.3% Cheuvreux – 11th German Corporate Conference, Freseni
Slide 23: Fresenius Helios: 2010 Restructuring Plan
Fresenius Helios: 2010 Restructuring Plan Years in portfolio <1 1 2 3 4 5 >5 Total No. of clinics - - 6 4 7 - 25 42 Revenue (€m) - - 186 261 175 - 1,607 2,229 Target EBITDA margin (%) - 3.0 6.0 9.0 12.0 15.0 15.0 EBITDA (€m) - - 11.2 23.5 20.9 - 241.1 296.7 Reported EBITDA margin (%) - - 4.0 10.8 11
Slide 24: Fresenius Helios: Performance Indicators
Fresenius Helios: Performance Indicators Q1-3/11 Q1-3/10 Change No. of hospitals1 64 62 3% - Acute care clinics 44 42 5% - Post-acute care clinics 20 20 0% No. of beds1 19,336 18,564 4% - Acute care clinics 15,869 15,097 5% - Post-acute care clinics 3,467 3,467 0% Admissions2 - Acute care (inpatient
Slide 25: Fresenius Vamed: Sales and EBIT in Line with Expectations
Fresenius Vamed: Sales and EBIT in Line with Expectations €m Q1-3/11 Q1-3/10 Growth Project business 311 351 -11% Service business 169 166 2% Total sales 480 517 -7% Total EBIT 22 24 -8% Margin 4.6% 4.6% Order intake1 335 418 -20% 2 Order backlog1 775 801 -3% 1 Project business only 2 Dec 31, 2010 C
Slide 26: Share Information
Share Information Share key facts Number of shares1 163,043,629 WKN / ISIN 578560 / DE0005785604 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de ADR key facts Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Ticker symbol FSNUY Exchange OTC-market Structure
Slide 27: Financial Calendar
Financial Calendar 21.02.2012 Report on Fiscal Year 2011 03.05.2012 Report on 1st quarter 2012 11.05.2012 Annual General Meeting, Frankfurt/Main 01.08.2012 Report on 1st half 2012 31.10.2012 Report on 1st – 3rd quarter 2012 Contact Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephon
Fresenius SE & Co. KGaA — Cheuvreux – 11th German Corporate Conference (January 2012) on 6ix